SEC Form 10-K filed by Brainstorm Cell Therapeutics Inc.
$BCLI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
Maxim Group upgraded Brainstorm Cell from Hold to Buy
Maxim Group upgraded Brainstorm Cell Therapeutics from Hold to Buy and set a new price target of $12.00
NEW YORK, April 10, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) for NurOwn®, the company's autologous mesenchymal stem cell therapy for amyotrophic lateral sclerosis (ALS). This important milestone sets the stage for the initiation of BrainStorm's highly anticipated Phase 3b clinical trial, which has been designed in collaboration with the FDA under a Special Protocol Assessment (SPA). The SPA agreement confirms that the Phase 3b trial design
Conference call and webcast at 8:30 a.m. Eastern Time today NEW YORK, March 31, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, and provided a corporate update. "2024 was a year of resilience and progress for BrainStorm as the company remained focused on its mission to develop and commercialize innovative therapies for neurodegenerative diseases. We had important accomplishments that reinforced our goal to gain regulatory approval of NurOwn in ALS and we continue to work closely with the FDA to achieve this,"
NEW YORK, March 26, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases, today announced that it has been granted the exact compliance extension it requested from the Nasdaq Hearings Panel through June 30, 2025, to regain compliance with certain continued listing standards of The Nasdaq Capital Market. BrainStorm presented its request for continued listing on The Nasdaq Capital Market and the relevant compliance plan to the Nasdaq Hearings Panel at the panel hearing held on February 25, 2025. As a
SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)
SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)
SC 13G/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)
Conference call and webcast at 8:30 a.m. Eastern Time today NEW YORK, March 31, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, and provided a corporate update. "2024 was a year of resilience and progress for BrainStorm as the company remained focused on its mission to develop and commercialize innovative therapies for neurodegenerative diseases. We had important accomplishments that reinforced our goal to gain regulatory approval of NurOwn in ALS and we continue to work closely with the FDA to achieve this,"
Call Scheduled for March 31, 2025, at 8:30 AM Eastern Time NEW YORK, March 24, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the fourth quarter and year ended December 31, 2024, at 8.30 a.m. Eastern Time on March 31, 2025. BrainStorm's President and Chief Executive Officer, Chaim Lebovits, will provide the update. Hartoun Hartounian, PhD, Chief Operating Officer, and Bob Dagher, MD, Chief Medical Officer, and Alla Patlis, interim Chief Financial Officer, will also participa
Call Scheduled for December 30, 2024, at 8:30 AM ET; Additionally, Key Opinion Leader Webinar on ALS Advancements to Take Place on December 11, 2024 NEW YORK, Dec. 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast on December 30, 2024, at 8:30 a.m. Eastern Time. BrainStorm's President and Chief Executive Officer, Chaim Lebovits, will provide the update. Hartoun Hartounian, PhD, Chief Operating Officer and EVP, and Bob Dagher, MD, Chief Development Officer, will also participate in the call. Following the prepared remarks,
8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
10-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
3/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK, June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024. Dr. Hartounian brings a distinguished track record with over 32 years of experience in the biopharmaceutical industry, with a focus on cell and gene therapy. His career highlights include founding and leading BioCentriq, a state-of-the-art cell and gene therapy CDMO facility, which was successfully acquired for $73 mil
Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases NEW YORK, July 12, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Bob Dagher, MD, as Executive Vice President and Chief Development Officer effective July 17, 2023. Dr. Dagher will serve on BrainStorm's executive leadership team reporting to Stacy Lindborg, Ph.D., co-CEO of BrainStorm. He will be responsible for the portfolio strategy and advancement of clinical development plans towards regulatory approval, includin
NEW YORK, June 20, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Nir Naor, CPA, CFA, MBA (IMD), LL.M, as Board Member, chairman of its Audit Committee and member of its Governance, Nomination and Compensation Committee (GNC), effective June 20. Mr. Naor is replacing Mr. Malcolm Taub, who will retire from the same roles after 14 years of service on the Company's board of directors. "We welcome the addition of Nir as a new independent board member, and we are confident that his impressive corporate experience in both the U.S. and Europe will add further
4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)